Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Block listing Interim Review

22 Jun 2020 07:00

RNS Number : 5608Q
Premier Veterinary Group PLC
22 June 2020
 

BLOCK LISTING SIX MONTHLY RETURN

 

Date: 22 June 2020

 

Name of applicant:

Premier Veterinary Group plc (formerly Ark Therapeutics Group plc)

 

Name of scheme:

2014 Ark Therapeutics Group plc Enterprise Management Incentive Share Option Plan

 

Period of return:

From:

21/12/2019

To:

20/06/2020

Balance of unallotted securities under scheme(s) from previous return:

369,035 ordinary shares of 10 pence each

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

Nil

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

369,035 ordinary shares of 10 pence each

     

 

 

Name of applicant:

Premier Veterinary Group plc (formerly Ark Therapeutics Group plc)

 

Name of scheme:

2014 Ark Therapeutics Group plc Unapproved Share Option Plan

 

Period of return:

From:

20/12/2019

To:

20/06/2020

Balance of unallotted securities under scheme(s) from previous return:

30,000 ordinary shares of 10 pence each

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

Nil

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

30,000 ordinary shares of 10 pence each

     

 

 

Name of contact:

Andy Paull, CFO

Telephone number of contact:

0117 370 0300

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRBUGDLISBDGGC
Date   Source Headline
10th Mar 20101:21 pmRNSEPT Disclosure
10th Mar 201011:52 amRNSEPT Disclosure
10th Mar 20107:00 amRNSFinal Results
9th Mar 20107:00 amRNSResearch Update
8th Mar 20105:34 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSResearch Update
19th Feb 20107:00 amRNSRe Agreement
16th Feb 20104:40 pmRNSSecond Price Monitoring Extn
16th Feb 20104:35 pmRNSPrice Monitoring Extension
11th Feb 201011:37 amRNSDirector/PDMR Shareholding
5th Feb 20104:35 pmRNSPrice Monitoring Extension
29th Jan 20103:23 pmRNSTotal Voting Rights
28th Jan 201011:05 amRNSNotice of Results
28th Jan 20107:02 amRNSResearch Update
28th Jan 20107:00 amRNSResearch Update
20th Jan 20103:51 pmRNSEmployee Benefit Trust
5th Jan 20107:00 amRNSArk files for re-examination of Cerepro
22nd Dec 20094:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20094:35 pmRNSPrice Monitoring Extension
18th Dec 200911:56 amRNSEMEA recommendation on Cerepro
15th Dec 20092:29 pmRNSHolding(s) in Company
3rd Dec 20092:41 pmRNSBlocklisting Interim Review
3rd Dec 20092:35 pmRNSHolding(s) in Company
24th Nov 20094:04 pmRNSHolding(s) in Company
11th Nov 20097:00 amRNSInterim Management Statement
14th Oct 20097:00 amRNSResearch Update
2nd Oct 200911:04 amRNSHolding(s) in Company
30th Sep 200910:51 amRNSHolding(s) in Company
29th Sep 20094:32 pmRNSHolding(s) in Company
4th Sep 20097:00 amRNSResearch Update
1st Sep 200912:08 pmRNSDirector/PDMR Shareholding
26th Aug 20097:00 amRNSResearch Update
26th Aug 20097:00 amRNSHalf Yearly Report
13th Jul 20097:00 amRNSArk launches Kerraglove woundcare device
1st Jul 20097:00 amRNSRe Agreement
26th Jun 20092:15 pmRNSHolding(s) in Company
24th Jun 20097:00 amRNSManufacturing Update
17th Jun 20097:00 amRNSRe Agreement
3rd Jun 200911:47 amRNSBlocklisting Interim Review
21st May 20097:00 amRNSTrinam Phase III Study Enrols First Patient
18th May 20097:00 amRNSInterim Management Statement
15th May 20097:00 amRNSCerepro Named Patient Supply approved in Finland
13th May 20094:41 pmRNSSecond Price Monitoring Extn
13th May 20094:35 pmRNSPrice Monitoring Extension
12th May 20097:00 amRNSDirector/PDMR Shareholding
6th May 20094:40 pmRNSSecond Price Monitoring Extn
6th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20097:00 amRNSTrinam(R) Awarded Fast Track Status by FDA
30th Apr 20094:01 pmRNSTotal Voting Rights
30th Apr 200912:00 pmRNSPrestigious European Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.